Adding Exenatide or Insulin Lispro to Insulin Glargine in T2DM.

• Research type

  Research Study

• Full title

  A Randomized Trial Comparing two therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects with Type 2 Diabetes, who were previously treated by Basal Insulin Glargine with either Metformin or Metformin and Sulfonylurea

• IRAS ID

  14560

• Contact name

  Arash Tahbaz

• Contact email

  tahbaz_arash@lilly.com

• Sponsor organisation

  Eli Lilly and Company Ltd.

• Eudract number

  2009-009500-39

• ISRCTN Number

  Not yet available

• Research summary

  Eli Lilly would prefer that a lay summary was not published on the NRES website at this stage. We would be happy to forward a summary within 21 days of first patient visit (planned on 15th September 2009), when this information will also be posted on the clinialtrials.gov website.

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  09/H0711/47

• Date of REC Opinion

  1 Jul 2009

• REC opinion

  Further Information Favourable Opinion